Design of enzyme decorated mucopermeating nanocarriers for eradication of H. pylori infection
Source abstract
Abstract
The study was aimed to develop amoxicillin (AM) loaded thiomer based mucopermeating and mucoadhesive nanocarrier system that allows it to reach the bacterium, hiding in deeper mucus layers and extends its availability at infection site. Amoxicillin loaded nanocargoes were prepared using unmodified polycarbophil (PCP), thiolated polycarbophil (PCP-Cys), and papain modified thiolated polycarbophil (PCP-Cys-PAP) by ionic gelation method and processed for in vitro and ex vivo and in vivo characterization. All the nanocargoes were in size range of 111–288 nm. Drug loaded papain modified thiolated polycarbophil (AM-PCP-Cys-PAP) based nanocargoes showed an entrapment efficiency of 78 ± 7.2%, a zeta potential of − 13.4 mV and spherical shape. Both AM-PCP-Cys and AM-PCP-Cys-PAP exhibited a sustained release of drug up to 48 h and AM-PCP-Cys-PAP nanocargoes showed significant stability in acidic pH as compared to pure drug. Rheological investigation demonstrated a twofold higher mucoadhesion for thiolated polycarbophil nanocargoes. Ex vivo muco-penetration studies demonstrated deepest permeation of papain modified nanocargoes into the mucus. Cytotoxicity analysis showed that nanocarrier formulations were non-toxic to Caco-2 cells and maintained cell viability after 48 h. In vitro growth inhibition assay for H. pylori exhibited better efficacy for AM-PCP-Cys-PAP nanocargoes in terms of improved stability along with complete eradication of bacteria over prolonged period of time. In vivo acute toxicity studies on vital organs of mice exhibited no significant change in cell morphology. In vivo clearance study showed that AM-PCP-Cys-PAP nanoformulation was successful in complete eradication of bacteria. Based on above findings, amoxicillin loaded papain modified thiolated polycarbophil nanocarrier system was able to completely eradicate H. pylori infection that was attributed to its enhanced mucopermeating and mucoadhesive nature. The functionalized nanocarriers showed an interesting future potential for infectious therapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Probiotics and Fermented Foods
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (49)
Show source-provided references
1. Arora S, Gupta S, Narang RK, Budhiraja RD (2011) Amoxicillin loaded chitosan–alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for H. pylori. Sci Pharm 79(3):673–69410.3797/scipharm.1011-05 ↗
2. Arora, S., Bisen, G., & Budhiraja, R. (2014). Mucoadhesive and muco-penetrating delivery systems for eradication of Helicobacter pylori. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 6(1)
3. Asija R (2014) Gastrointestinal mucoadhesive drug delivery system: an overview. J Drug Discov Ther 2(20):213–219
4. Balzus B, Colombo M, Sahle FF, Zoubari G, Staufenbiel S, Bodmeier R (2016) Comparison of different in vitro release methods used to investigate nanocarriers intended for dermal application. Int J Pharm 513(1–2):247–25410.1016/j.ijpharm.2016.09.033 ↗
5. Barthelmes J, Dünnhaupt S, Unterhofer S, Perera G, Schlocker W, Bernkop-Schnürch A (2013) Thiolated particles as effective intravesical drug delivery systems for treatment of bladder-related diseases. Nanomedicine 8(1):65–7510.2217/nnm.12.76 ↗
6. Bergin IL, Witzmann FA (2013) Nanoparticle toxicity by the gastrointestinal route: evidence and knowledge gaps. Int J Biomed Nanosci Nanotechnol 3(1–2):49–58
7. Bernkop-Schnürch A (2005) Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev 57(11):1569–158210.1016/j.addr.2005.07.002 ↗
8. Bernkop-Schnürch A, Gilge B (2000) Anionic mucoadhesive polymers as auxiliary agents for the peroral administration of (poly) peptide drugs: influence of the gastric juice. Drug Dev Ind Pharm 26(2):107–11310.1081/DDC-100100335 ↗
9. Bernkop-Schnürch A, Scholler S, Biebel RG (2000) Development of controlled drug release systems based on thiolated polymers. J Control Release 66(1):39–4810.1016/S0168-3659(99)00256-4 ↗
10. Bernkop-Schnürch A, Weithaler A, Albrecht K, Greimel A (2006) Thiomers: preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system. Int J Pharm 317(1):76–8110.1016/j.ijpharm.2006.02.044 ↗
11. Boegh M, Garcia-Diaz M, Müllertz A, Nielsen H (2015) Steric and interactive barrier properties of intestinal mucus elucidated by particle diffusion and peptide permeation. Eur J Pharm Biopharm 95:1–8. https://doi.org/10.1016/j.ejpb.2015.01.01410.1016/j.ejpb.2015.01.014 ↗
12. Cevher E, Sensoy D, Taha MA, Araman A (2008) Effect of thiolated polymers to textural and mucoadhesive properties of vaginal gel formulations prepared with polycarbophil and chitosan. AAPS PharmSciTech 9(3):953–96510.1208/s12249-008-9132-y ↗
13. Clausen AE, Bernkop-Schnürch A (2000) In vitro evaluation of the permeation-enhancing effect of thiolated polycarbophil. J Pharm Sci 89(10):1253–126110.1002/1520-6017(200010)89:10<1253::AID-JPS3>3.0.CO;2-8 ↗
14. Cone RA (2009) Barrier properties of mucus. Adv Drug Deliv Rev 61(2):75–8510.1016/j.addr.2008.09.008 ↗
15. Crater JS, Carrier RL (2010) Barrier properties of gastrointestinal mucus to nanoparticle transport. Macromol Biosci 10(12):1473–148310.1002/mabi.201000137 ↗
16. da Silva CR, Oliveira MB, Motta ES, de Almeida GS, Varanda LL, de Pádula M, Leitão AC, Caldeira-de-Araújo A (2010) Genotoxic and cytotoxic safety evaluation of papain (Carica papaya L.) using in vitro assays. Biomed Res Int 2010:75–88
17. Dünnhaupt S, Barthelmes J, Hombach J, Sakloetsakun D, Arkhipova V, Bernkop-Schnürch A (2011) Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa. Int J Pharm 408(1):191–19910.1016/j.ijpharm.2011.01.060 ↗
18. Dünnhaupt S, Barthelmes J, Köllner S, Sakloetsakun D, Shahnaz G, Düregger A, Bernkop-Schnürch A (2015) Thiolated nanocarriers for oral delivery of hydrophilic macromolecular drugs. Carbohydr Polym 117:577–58410.1016/j.carbpol.2014.09.078 ↗
19. Gautam MK, Goel RK (2014) Toxicological study of Ocimum sanctum linn leaves: hematological, biochemical, and histopathological studies. J Toxicol 2014:135654. https://doi.org/10.1155/2014/13565410.1155/2014/135654 ↗
20. Greindl M, Bernkop-Schnürch A (2006) Development of a novel method for the preparation of thiolated polyacrylic acid nanoparticles. Pharm Res 23(9):2183–218910.1007/s11095-006-9087-1 ↗
21. Hanefeld U, Gardossi L, Magner E (2009) Understanding enzyme immobilisation. Chem Soc Rev 38(2):453–46810.1039/B711564B ↗
22. Homaei AA, Sajedi RH, Sariri R, Seyfzadeh S, Stevanato R (2010) Cysteine enhances activity and stability of immobilized papain. Amino Acids 38(3):937–94210.1007/s00726-009-0302-3 ↗
23. Iqbal J, Shahnaz G, Perera G, Hintzen F, Sarti F, Bernkop-Schnürch A (2012) Thiolated chitosan: development and in vivo evaluation of an oral delivery system for leuprolide. Eur J Pharm Biopharm 80(1):95–10210.1016/j.ejpb.2011.09.010 ↗
24. Kaul P, Sathish H, Prakash V (2002) Effect of metal ions on structure and activity of papain from Carica papaya. Mol Nutr Food Res 46(1):2–6
25. Köllner S, Dünnhaupt S, Waldner C, Hauptstein S, de Sousa IP, Bernkop-Schnürch A (2015) Mucus permeating thiomer nanoparticles. Eur J Pharm Biopharm 97:265–27210.1016/j.ejpb.2015.01.004 ↗
26. Kumar D, Dharmendra S, Jhansee M, Shrikant N, Pandey S (2011) Development and characterization of chitosan nanoparticles loaded with amoxicillin. Int Res J Phar 2:145–511
27. Laffleur F, Hintzen F, Shahnaz G, Rahmat D, Leithner K, Bernkop-Schnürch A (2014) Development and in vitro evaluation of slippery nanoparticles for enhanced diffusion through native mucus. Nanomedicine 9(3):387–39610.2217/nnm.13.26 ↗
28. Lai SK, Wang Y-Y, Hanes J (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61(2):158–17110.1016/j.addr.2008.11.002 ↗
29. Lam HT, Leonaviciute G, Zupančič O, Bernkop-Schnürch A (2017) Thiomers: impact of in situ cross-linkers on mucoadhesive properties. Eur J Pharm Sci 106:41–4810.1016/j.ejps.2017.05.051 ↗
30. Marques MR, Loebenberg R, Almukainzi M (2011) Simulated biological fluids with possible application in dissolution testing. Dissolution Technol 18(3):15–2810.14227/DT180311P15 ↗
31. Mehta SB, Carpenter JF, Randolph TW (2016) Colloidal instability fosters agglomeration of subvisible particles created by rupture of gels of a monoclonal antibody formed at silicone oil-water interfaces. J Pharm Sci 105(8):2338–234810.1016/j.xphs.2016.06.010 ↗
32. Metin AÜ, Alver E (2016) Fibrous polymer-grafted chitosan/clay composite beads as a carrier for immobilization of papain and its usability for mercury elimination. Bioprocess Biosyst Eng 39(7):1137–114910.1007/s00449-016-1590-0 ↗
33. Müller C, Leithner K, Hauptstein S, Hintzen F, Salvenmoser W, Bernkop-Schnürch A (2013) Preparation and characterization of mucus-penetrating papain/poly (acrylic acid) nanoparticles for oral drug delivery applications. J Nanopart Res 15(1):135310.1007/s11051-012-1353-z ↗
34. Müller C, Perera G, König V, Bernkop-Schnürch A (2014) Development and in vivo evaluation of papain-functionalized nanoparticles. Eur J Pharm Biopharm 87(1):125–13110.1016/j.ejpb.2013.12.012 ↗
35. Narkar M, Sher P, Pawar A (2010) Stomach-specific controlled release gellan beads of acid-soluble drug prepared by ionotropic gelation method. AAPS PharmSciTech 11(1):267–27710.1208/s12249-010-9384-1 ↗
36. Novelli F, De Santis S, Punzi P, Giordano C, Scipioni A, Masci G (2017) Self-assembly and drug release study of linear l, d-oligopeptide-poly (ethylene glycol) conjugates. New Biotechnol 37(5):99–10710.1016/j.nbt.2016.07.005 ↗
37. Patel JK, Chavda JR (2009) Formulation and evaluation of stomach-specific amoxicillin-loaded carbopol-934P mucoadhesive microspheres for anti-Helicobacter pylori therapy. J Microencapsul 26(4):365–376. https://doi.org/10.1080/0265204080237301210.1080/02652040802373012 ↗
38. Pearson JP, Chater PI, Wilcox MD (2016) The properties of the mucus barrier, a unique gel – how can nanoparticles cross it? Ther Deliv 7(4):229–244. https://doi.org/10.4155/tde-2015-000210.4155/tde-2015-0002 ↗
39. Rajinikanth P, Balasubramaniam J, Mishra B (2007) Development and evaluation of a novel floating in situ gelling system of amoxicillin for eradication of Helicobacter pylori. Int J Pharm 335(1):114–12210.1016/j.ijpharm.2006.11.008 ↗
40. Rossi A, Conti C, Colombo G, Castrati L, Scarpignato C, Barata P, Sandri G, Caramella C, Bettini R, Buttini F (2016) Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. Drug Dev Ind Pharm 42(2):332–33910.3109/03639045.2015.1054397 ↗
41. Sambuy Y, De Angelis I, Ranaldi G, Scarino M, Stammati A, Zucco F (2005) The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 21(1):1–2610.1007/s10565-005-0085-6 ↗
42. Shahnaz G, Perera G, Sakloetsakun D, Rahmat D, Bernkop-Schnürch A (2010) Synthesis, characterization, mucoadhesion and biocompatibility of thiolated carboxymethyl dextran–cysteine conjugate. J Control Release 144(1):32–3810.1016/j.jconrel.2010.01.033 ↗
43. Shahzadi I, Dizdarevic A, Efiana NA, Matuszczak B, Bernkop-Schnurch A (2018) Trypsin decorated self-emulsifying drug delivery systems (SEDDS): key to enhanced mucus permeation. J Colloid Interface Sci 531:253–260. https://doi.org/10.1016/j.jcis.2018.07.05710.1016/j.jcis.2018.07.057 ↗
44. Sigurdsson HH, Kirch J, Lehr C-M (2013) Mucus as a barrier to lipophilic drugs. Int J Pharm 453(1):56–6410.1016/j.ijpharm.2013.05.040 ↗
45. Sohail MF, Javed I, Hussain SZ, Sarwar S, Akhtar S, Nadhman A, Batool S, Bukhari NI, Saleem RSZ, Hussain I (2016) Folate grafted thiolated chitosan enveloped nanoliposomes with enhanced oral bioavailability and anticancer activity of docetaxel. J Mater Chem B 4(37):6240–624810.1039/C6TB01348A ↗
46. Umamaheshwari RB, Jain NK (2003) Receptor mediated targeting of lectin conjugated gliadin nanoparticles in the treatment of Helicobacter pylori. J Drug Target 11(7):415–424. https://doi.org/10.1080/1061186031000164777110.1080/10611860310001647771 ↗
47. Umamaheshwari R, Ramteke S, Jain NK (2004) Anti-Helicobacter pylori effect of mucoadhesive nanoparticles bearing amoxicillin in experimental gerbils model. AAPS PharmSciTech 5(2):60–6810.1208/pt050232 ↗
48. Vetter A, Martien R, Bernkop-Schnürch A (2010) Thiolated polycarbophil as an adjuvant for permeation enhancement in nasal delivery of antisense oligonucleotides. J Pharm Sci 99(3):1427–143910.1002/jps.21887 ↗
49. Zazo H, Colino CI, Lanao JM (2016) Current applications of nanoparticles in infectious diseases. J Control Release 224:86–10210.1016/j.jconrel.2016.01.008 ↗